Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib effect on Caffeine PK in healthy participants
NCT04655040Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Primary endpoint: Area under the plasma concentration-time profile from time 0 extrapolated to infinity of caffeine at Day 8. Started Dec 2020; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04655040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655040.